Clinical trials: Sweating
Primary Axillary Hyperhidrosis
Evaluation of N-SWEAT Patch for Treatment of Primary Axillary Hyperhidrosis or Excessive Axillary Sweating
The Sahara Study is a study to evaluate the safety and effectiveness of the N-SWEAT Patch for use in subjects with excessive axillary sweating, or primary focal axillary hyperhidrosis.
- Trial name
- NCT04599907
- Testing
- Roll-In Cohort: Single Application of N-SWEAT Patch, Randomized Cohort: Single Application of N-SWEAT Patch
- Where
- 9 sites in United States
- Volunteers
- 120 people
- Sponsor
- Candesant Biomedical, Inc.
Hidradenitis Suppurativa
A Study to Evaluate the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa
The purpose of the study is to evaluate the efficacy and safety of bimekizumab in study participants with moderate to severe hidradenitis suppurativa (HS)
- Trial name
- BE HEARD II (NCT04242498)
- Testing
- Bimekizumab
- Where
- 91 sites in United States, Australia and 12 more
- Volunteers
- 509 people
- Sponsor
- UCB Biopharma SRL
Electrolyte Imbalance, Hyponatremia
V2 Receptor Effects on Fluid Regulation and Performance
This primary aim of this study was to critically assess whether or not sweat water content and sodium concentration were acutely regulated by dynamic changes in antidiuretic hormone (arginine vasopressin or AVP) acting on the…
- Conditions
- Electrolyte Imbalance, Hyponatremia, Hypernatremia
- Trial name
- NCT02084797
- Testing
- V2R (Vasopressin 2 receptor)
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Oakland University
Healthy
Controlled Randomized Study With Athena Base Plate Versus SenSura Base Plate on Perspiring Skin
Aim The aim of the Athena project is to develop an ostomy product that is softer and more flexible in order to improve the comfort for people with a stoma.
- Trial name
- NCT01245413
- Testing
- SenSura, Athena
- Where
- Denmark
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Coloplast A/S
Acne Inversa
A Study to Evaluate the Safety and Efficacy of PF-06650833, PF-06700841, and PF 06826647 in Adults With Hidradenitis Suppurativa
This is a study with 3 kinase inhibitors (PF 06650833, PF 06700841 and PF 06826647) in participants with moderate to severe HS. The study will have a maximum duration of approximately 26 weeks.
- Trial name
- NCT04092452
- Testing
- PF-06650833, PF-06700841, PF-06826647
- Where
- 77 sites in United States, Australia and 1 more
- Volunteers
- 194 people
- Sponsor
- Pfizer
Cystic Fibrosis
Early Signs of Efficacy Study With Riociguat in Adult Homozygous Delta F508 Cystic Fibrosis Patients
Assessment of the safety, tolerability and early signs of efficacy of three times a day orally administered BAY63-2521 in adult delta F508 homozygous Cystic Fibrosis patients not on treatment with Orkambi
- Trial name
- NCT02170025
- Testing
- Riociguat (Adempas, BAY63-2521)
- Where
- 10 sites in United States, Belgium and 5 more
- Volunteers
- 21 people
- Sponsor
- Bayer
Hidradenitis Suppurativa (HS)
Efficacy and Safety Study of Adalimumab in Treatment of Hidradenitis Suppurativa
A study to evaluate the safety and efficacy of treatment with adalimumab in adults with moderate to severe hidradenitis suppurativa (HS).
- Trial name
- PIONEER I (NCT01468207)
- Testing
- adalimumab
- Volunteers
- 307 people
- Sponsor
- AbbVie (prior sponsor, Abbott)
Hidradenitis Suppurativa, Hidradenitis
Low Dose Radiotherapy for Advanced Hidradenitis Suppurativa
To establish the safety of radiotherapy in the treatment of advanced hidradenitis suppurativa. Patients will receive radiotherapy treatment over one week and then they will be followed for the next three months.
- Trial name
- RTHS (NCT03040804)
- Testing
- Low dose Radiotherapy
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Montefiore Medical Center
Cystic Fibrosis
Short Term Effects of Ivacaftor in Non-G551D Cystic Fibrosis Patients
This is a study of the short-term effects of ivacaftor on sweat chloride concentration and lung function in cystic fibrosis (CF) patients who fall outside current FDA approval.
- Trial name
- NCT01784419
- Testing
- ivacaftor
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- University of California, San Francisco
Cystic Fibrosis
(Study: Vertex IIS) Does Ivacaftor Alter Wild Type CFTR-Open Probability In The Sweat Gland Secretory Coil?
Clinical studies of lumacaftor + ivacaftor (combo therapy) produced better FEV1 (forced expiratory volume in 1 second) improvements than ivacaftor alone, without further improvement in sweat chloride results.
- Trial name
- NCT02310789
- Testing
- Ivacaftor, β-Adrenergic cocktail, Pilocarpine Nitrate 5%
- Where
- United States
- Volunteers
- 8 people, healthy volunteers welcome
- Sponsor
- Richard Barry Moss
Stability & Variability of Lipid-derived Molecules in Sweat
Investigating the Stability, Variability and Mechanism of Incorporation of Lipid Mediators Into Eccrine Sweat
The purpose of this study is to see what the differences are in sweat (amount and small molecule content) collected from different sites of the body and by different methods of sweat stimulation.
- Trial name
- NCT02935894
- Testing
- Ibuprofen, Physiological induction of sweating, Pilocarpine
- Where
- United States
- Volunteers
- 14 people, healthy volunteers welcome
- Sponsor
- USDA, Western Human Nutrition Research Center
Hidradenitis Suppurativa
A Global Study Comparing Risankizumab to Placebo in Adult Participants With Moderate to Severe Hidradenitis Suppurativa
The primary objective of this study is to assess the safety and efficacy of risankizumab 180 mg and 360 mg versus placebo for the treatment of signs and symptoms of moderate to severe hidradenitis suppurativa (HS) in adult…
- Trial name
- DETERMINED 1 (NCT03926169)
- Testing
- Risankizumab
- Where
- 59 sites in United States, Australia and 6 more
- Volunteers
- 243 people
- Sponsor
- AbbVie
Hot Flashes
Breathe for Hot Flashes Randomized Controlled Trial
Background: Paced respiration has been internationally recommended for vasomotor symptom management despite limited empirical evidence.
- Trial name
- NCT00819182
- Testing
- Paced respiration
- Where
- United States
- Volunteers
- 218 people, healthy volunteers welcome
- Sponsor
- Indiana University
Hidradenitis Suppurativa
Evaluation of Sonelokimab for the Treatment of Patients With Active Moderate to Severe Hidradenitis Suppurativa
This is a study to demonstrate the clinical efficacy and safety of the nanobody® sonelokimab administered subcutaneously (sc) compared with placebo in the treatment of adult participants with moderate to severe hidradenitis…
- Trial name
- NCT05322473
- Testing
- Sonelokimab (M1095), Adalimumab
- Where
- 57 sites in United States, Bulgaria and 5 more
- Volunteers
- 234 people
- Sponsor
- MoonLake Immunotherapeutics AG
Hidradenitis Suppurativa
Study of Adalimumab in Subjects With Moderate to Severe Chronic Hidradenitis Suppurativa
This study will investigate how well adalimumab works in people with hidradenitis suppurativa (HS) in the short and long term.
- Trial name
- NCT00918255
- Testing
- adalimumab
- Where
- 26 sites in United States, Denmark and 2 more
- Volunteers
- 154 people
- Sponsor
- Abbott
Hidradenitis Suppurativa
Evaluating the Effect of a Written Action Plan on Comfort and Understanding of Hidradenitis Suppurativa
This study is being conducted to evaluate if a written action plan for hidradenitis suppurativa (HS) will help patients with hidradenitis suppurativa gain a better understanding of the condition and how to manage the condition on…
- Trial name
- NCT04600375
- Testing
- Verbal consultation, Written Action Plan
- Where
- United States
- Volunteers
- 22 people
- Sponsor
- University of Arkansas
Hidradenitis Suppurativa
Hidradenitis Suppurativa (HS) Tunneling Wounds
The purpose of this study is to look at the change in the microbiome (bacterial composition) of an HS tunneling wound and examine if treatment with an antibiofilm surfactant wound gel (ABWG) (a topical medication that will fight…
- Trial name
- NCT04648631
- Testing
- antibiofilm surfactant wound gel (ABWG)
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Miami
Hyperhidrosis
Study of Glycopyrronium in Subjects With Axillary Hyperhidrosis
The study is a randomized, double-blind, vehicle controlled, parallel group study, designed to assess the efficacy and safety of glycopyrronium topical wipes, once daily, compared to vehicle in subjects with axillary…
- Trial name
- NCT02530294
- Testing
- glycopyrronium Topical Wipes, Vehicle
- Where
- 20 sites in United States
- Volunteers
- 353 people
- Sponsor
- Journey Medical Corporation
Hyperhidrosis
Long-term Safety Study of Glycopyrronium in Subjects With Primary Axillary Hyperhidrosis
This is an open-label, long-term safety study of glycopyrronium topical wipes, enrolling up to 660 subjects with primary axillary hyperhidrosis who participated in either the DRM04-HH04 or DRM04-HH05 studies.
- Trial name
- NCT02553798
- Testing
- Glycopyrronium Topical Wipes
- Where
- 48 sites in United States, Germany
- Volunteers
- 564 people
- Sponsor
- Journey Medical Corporation
Hidradenitis Suppurativa
Study of Efficacy and Safety of Investigational Treatments in Patients With Moderate to Severe Hidradenitis Suppurativa
The main purpose of this study is to assess preliminary efficacy and safety of CFZ533/iscalimab (Cohort A), LYS006 (Cohort B), MAS825 (Cohort C), LOU064/remibrutinib (Cohort D) and VAY736/ianalumab (Cohort E) in patients with…
- Trial name
- NCT03827798
- Testing
- CFZ533, LYS006, MAS825
- Where
- 36 sites in United States, Austria and 9 more
- Volunteers
- 248 people
- Sponsor
- Novartis Pharmaceuticals